VivoSeq
Oncology

B Acute Lymphoblastic Leukemia

28

Pipeline Programs↗

7

Active Trials↗

18

Companies Involved↗

B Acute Lymphoblastic Leukemia is an emerging landscape with 28 programs across 18 companies. The most active players are Bellicum Pharmaceuticals, Sanofi, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 21 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

0/100

Mech. Concentration

19/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Bellicum Pharmaceuticals

1 program

Phase 1Sanofi logo

Sanofi

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2H

Hikma Pharmaceuticals LLC

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

68%

Small molecule

19 of 28 classified programs — the dominant modality here.

32%ALL OTHERSProtein / enzyme518%Monoclonal antibody27%Antibody–drug conjugate14%Cell therapy14%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 93% of 30 pipeline programs.

Analysis

Trial Status

7

clinical trials

Active, not recruiting4 · 57%
Recruiting3 · 43%

Clinical Trials

Trial Activity

7 trials

An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06124157·222 enrolled
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT03150693·303 enrolled
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Recruiting·Children's Oncology Group·Phase 3·NCT03959085·5,951 enrolled
A Randomized Phase II Study Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Plus Blinatumomab Compared to Usual Chemotherapy Plus Blinatumomab for Older Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Active, not recruiting·Alliance for Clinical Trials in Oncology·Phase 2·NCT05303792·68 enrolled
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Active, not recruiting·Children's Oncology Group·Phase 3·NCT05602194·440 enrolled
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT03914625·6,720 enrolled
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Active, not recruiting·SStanford University·Phase 1·NCT03241940·33 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)